
Covid-19 vaccine for 5- to 11-year-olds is safe and shows 'robust' antibody response, Pfizer says
CNN
A Phase 2/3 trial of Pfizer/BioNTech's two-dose Covid-19 vaccine for children ages 5 to 11 showed it is safe and generated a "robust" antibody response.
These are the first such results released for this age group for a US Covid-19 vaccine, and the data has not yet been peer-reviewed or published. Pfizer said it plans to submit to the US Food and Drug Administration for emergency use authorization soon.
The trial included 2,268 participants ages 5 to 11 and used a two-dose regimen of the vaccine administered 21 days apart. This trials used a 10-microgram dose -- smaller than the 30-microgram dose that has been used for those 12 and older.

Janet Mills and her allies are counting on a gender gap to narrow Platner’s wide lead ahead of the June 9 primary to decide who will face incumbent Republican Sen. Susan Collins. They are betting that the unfiltered style that has brought Platner widespread attention as someone who could help Democrats reach young men will backfire with women.

As a shrinking number of Transportation Security Administration agents work to keep hourslong security lines moving despite not being paid, President Donald Trump stepped into the fray Saturday, announcing he will send Immigration and Customs Enforcement officers to airports by Monday if Congress doesn’t agree to a plan to end the partial government shutdown.











